Skip to main content
PharmaResources (Shanghai) Co., Ltd. logo

PharmaResources (Shanghai) Co., Ltd. — Investor Relations & Filings

Ticker · 301230 ISIN · CNE1000065Q9 Shenzhen Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 458 across all filing types
Latest filing 2024-04-23 Notice of Dividend Amou…
Country CN China
Listing Shenzhen Stock Exchange 301230

About PharmaResources (Shanghai) Co., Ltd.

https://www.pharmaresources.cn

PharmaResources (Shanghai) Co., Ltd. is a comprehensive Contract Research Organization (CRO) and Contract Development and Manufacturing Organization (CDMO) specializing in small molecule drug discovery and development. The company provides an integrated platform of services including medicinal chemistry, custom synthesis, process research and development, and analytical chemistry. PharmaResources supports global pharmaceutical and biotechnology partners through the entire drug development lifecycle, from initial lead optimization to the commercial-scale manufacturing of advanced intermediates and Active Pharmaceutical Ingredients (APIs). With a focus on technical innovation and quality management, the firm utilizes advanced synthetic methodologies and process engineering to accelerate drug candidates toward clinical trials and market approval.

Recent filings

Filing Released Lang Actions
关于2024年中期利润分配计划的公告
Notice of Dividend Amount Classification · 95% confidence The document is a public announcement from Shanghai Hongbo Zhiyuan Pharmaceutical Co., Ltd. regarding the 2024 interim profit distribution plan. It discusses the proposal for a cash dividend based on the company's net profit for the period and mentions that the plan has been approved by the board and supervisory committee and will be submitted to the 2023 annual shareholders meeting for approval. The document is short (619 characters) and serves as an announcement of a dividend plan rather than the actual dividend payment or detailed financial report. Therefore, it fits the category of Notice of Dividend Amount (DIV), which covers announcements of dividend amounts, payment dates, and related shareholder information.
2024-04-23 Chinese
中信证券股份有限公司关于上海泓博智源医药股份有限公司使用剩余超募资金永久补充流动资金的核查意见
Capital/Financing Update Classification · 95% confidence The document is a formal opinion from a sponsoring securities company (中信证券股份有限公司) regarding the use of remaining over-raised funds by Shanghai Hongbo Zhiyuan Pharmaceutical Co., Ltd. It discusses the approval process by the board, supervisory committee, and shareholders' meeting for using surplus funds to permanently supplement working capital. The document references regulatory guidelines and approvals related to the use of raised funds from an IPO. It is not a full financial report, earnings release, or audit report, but rather a regulatory compliance and verification opinion related to capital use. The document length is about 2405 characters, relatively short and focused on a specific capital use matter. This fits best under Capital/Financing Update (CAP) as it updates on the use of capital raised from the IPO and compliance with regulatory requirements for such use.
2024-04-23 Chinese
关于续聘会计师事务所的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the reappointment of an accounting firm (立信会计师事务所) as the auditor for the company for the 2024 fiscal year. It details the auditor's qualifications, past performance, independence, and audit fees, and mentions that the appointment is subject to shareholder approval at the 2023 annual general meeting. The document does not contain any financial statements or substantive financial data itself, but rather is a formal announcement about the auditor appointment process and related board resolutions. The document length is 3483 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, this document fits best into the category of Regulatory Filings (RNS) as it is a regulatory announcement about auditor reappointment rather than the audit report or annual report itself.
2024-04-23 Chinese
关于首次公开发行股票募投项目结项并使用节余募集资金永久补充流动资金的公告
Capital/Financing Update Classification · 95% confidence The document is an official announcement from Shanghai Hongbo Zhiyuan Pharmaceutical Co., Ltd. regarding the completion of a fundraising project related to their initial public offering (IPO) and the permanent use of surplus raised funds to supplement working capital. It details the fundraising amounts, project investment, management and storage of funds, reasons for surplus funds, and approvals from the board and supervisory committee. The document includes references to regulatory compliance and approvals but does not contain financial statements or detailed financial performance data. It is a regulatory announcement about the use of capital raised from an IPO, specifically about the conclusion of a fundraising project and the reallocation of surplus funds. This fits the category of a Capital/Financing Update (CAP) rather than a full financial report or other categories. The document length is about 4943 characters, which is sufficient for a detailed announcement but not a full annual or interim report. Therefore, the best classification is Capital/Financing Update (CAP).
2024-04-23 Chinese
董事会审计委员会关于所对会计师事务所2023年度履职情况评估及履行监督职责情况的报告
Audit Report / Information Classification · 95% confidence The document is a report from the Board Audit Committee evaluating the performance and supervision of the accounting firm (立信会计师事务所) for the fiscal year 2023. It discusses the audit firm's qualifications, the audit process, communication with management, and the issuance of an unqualified audit opinion on the 2023 financial statements. The document is focused on the audit report and the committee's oversight of the auditor's work, rather than the full annual report itself. It is not a full Annual Report (10-K) but rather a standalone audit-related report. Therefore, it fits the definition of an Audit Report / Information (AR). The document length is 2231 characters, which is relatively short but contains substantive audit evaluation content, not just an announcement or certification. Hence, the classification is AR with high confidence. FY 2023
2024-04-23 Chinese
中信证券股份有限公司关于上海泓博智源医药股份有限公司2023年度募集资金存放与使用情况专项核查报告
Audit Report / Information Classification · 95% confidence The document is titled as a "2023年度募集资金存放与使用情况专项核查报告" which translates to "2023 Annual Special Verification Report on the Deposit and Use of Raised Funds". It is issued by the sponsor (中信证券股份有限公司) for the company 上海泓博智源医药股份有限公司. The content details the use, management, and storage of funds raised from the company's initial public offering (IPO) in 2022, including amounts raised, usage, investment projects, and compliance with regulatory requirements. It also includes verification opinions from an accounting firm and the sponsor's review. This type of document is a specialized audit or verification report focusing on the use of raised funds, not a full annual report or earnings release. It is a standalone audit-related report concerning regulatory compliance on fundraising usage. Therefore, it fits the category of Audit Report / Information (AR). The document length is substantial and contains detailed financial and compliance data, not just an announcement or certification, so it is not RPA or RNS. Hence, the classification is AR with high confidence. FY 2023
2024-04-23 Chinese

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.